Lifeward Ltd. LFWD
- Market cap
- $19.7M
- P/E
- 0.0×
Follow LFWD
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5,355.00 | 2,205.00 | 338.10 | 155.40 | 34.44 | 97.44 | 58.80 | 47.04 | 16.92 | 6.01 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 33,201.00 | 7,560.00 | 2,835.00 | 846.72 | 227.64 | 504.00 | 110.88 | 74.76 | 109.20 | 48.00 |
High Price
|
|||
| 94 | 65 | 58 | 50 | 49 | 51 | 56 | 108 | 80 | 81 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 6 | 8 | 7 | 5 | 4 | 6 | 6 | 14 | 26 | 22 |
Revenue
|
|||
| 12.54% | 40.00% | 43.16% | 55.94% | 49.83% | 48.66% | 34.57% | 32.14% | 32.01% | 38.25% |
Gross Margin
|
|||
| (32) | (25) | (22) | (16) | (13) | (13) | (19) | (22) | (29) | (20) |
EBT
|
|||
| (553.76%) | (317.27%) | (331.25%) | (318.98%) | (294.22%) | (211.90%) | (346.62%) | (159.85%) | (112.61%) | (90.63%) |
EBT Margin
|
|||
| (33) | (25) | (22) | (16) | (13) | (13) | (20) | (22) | (29) | (20) |
Net Income
|
|||
| 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 0 |
Depreciation
|
|||
| 931.59 | 807.60 | 374.00 | 71.04 | 23.40 | 10.46 | 7.42 | 19.50 | 35.43 | 18.98 |
Revenue/Sh
|
|||
| (5,187.52) | (2,562.26) | (1,239.12) | (226.82) | (68.89) | (22.68) | (26.04) | (31.08) | (39.98) | (17.16) |
Earnings/Sh
|
|||
| (4,370.95) | (2,339.79) | (844.23) | (215.96) | (67.07) | (20.10) | (24.10) | (29.08) | (29.98) | (14.49) |
Cash Flow/Sh
|
|||
| (69.37) | (2.19) | (0.74) | (0.32) | (0.39) | (0.08) | (0.03) | (0.11) | 0.00 | (0.01) |
Capex/Sh
|
|||
| (4,440.32) | (2,341.98) | (844.97) | (216.28) | (67.46) | (20.18) | (24.13) | (29.20) | (29.98) | (14.51) |
Free CF/Sh
|
|||
| 1,311.11 | 386.15 | 111.14 | 157.14 | 116.00 | 156.65 | 91.80 | 65.45 | 26.02 | 7.24 |
Book Value/Sh
|
|||
| 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 6.76 | 2.93 | 0.98 | 2.55 | 4.74 | 9.88 | 8.54 | 3.83 | 0.59 | 0.36 |
PS Ratio
|
|||
| 4.81 | 6.12 | 3.29 | 1.15 | 0.96 | 0.66 | 0.69 | 1.14 | 0.80 | 0.96 |
PB Ratio
|
|||
| 5.80 | 3.03 | 0.85 | 0.65 | 0.47 | (4.75) | (3.61) | 1.96 | 0.40 | 0.42 |
EV/Sales
|
|||
| (1.22) | (1.04) | (0.37) | (0.21) | (0.16) | 2.46 | 1.11 | (1.31) | (0.47) | (0.55) |
EV/FCF
|
|||
| (28) | (22) | (15) | (15) | (13) | (11) | (18) | (21) | (22) | (17) |
Op' Cash Flow
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 |
Capex
|
|||
| (28) | (22) | (15) | (15) | (13) | (12) | (18) | (21) | (22) | (17) |
FCF
|
|||
| 17 | 11 | 8 | 11 | 21 | 88 | 68 | 27 | 11 | 4 |
Working Cap'
|
|||
| 18 | 15 | 9 | 7 | 2 | 1 | 1 | — | — | 3 |
Total Debt
|
|||
| (6) | 1 | (1) | (9) | (19) | (87) | (67) | (28) | (7) | 0 |
Net Debt
|
|||
| 8 | 4 | 2 | 11 | 22 | 89 | 68 | 47 | 19 | 8 |
Sh' Equity
|
|||
| (113.38%) | (90.50%) | (114.61%) | (79.07%) | (49.49%) | (20.74%) | (23.16%) | (32.21%) | (61.79%) | (74.60%) |
ROA
|
|||
| (733.16%) | (305.99%) | (1,105.78%) | (588.47%) | (249.50%) | (375.74%) | (1,023.91%) | (80.09%) | (154.06%) | (139.70%) |
ROIC
|
|||
| (222.78%) | (413.09%) | (766.99%) | (244.42%) | (79.72%) | (22.92%) | (24.84%) | (38.60%) | (88.56%) | (146.12%) |
ROE
|
|||
Lifeward Ltd. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| MODD Modular Medical, Inc. | $17.7M | 0.0× | Compare |
| ALUR Allurion Technologies, Inc. | $16.7M | 0.0× | Compare |
| HSCS HeartSciences Inc. | $23.9M | 0.0× | Compare |
| RBOT Vicarious Surgical Inc. | $14.3M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ARAY Accuray Incorporated | $27.8M | 0.0× | Compare |
| CTSO Cytosorbents Corporation | $13.6M | 0.0× | Compare |
| PETV PetVivo Holdings, Inc. | $12.9M | 0.0× | Compare |
| PAVM PAVmed Inc. | $31.0M | 0.0× | Compare |
Lifeward Ltd. (LFWD) key facts
- Lifeward Ltd. (LFWD) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Lifeward Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $22.0 million, down 14.1% from fiscal 2024.
- As of September 25, 2026, LFWD traded at $6.99, a market capitalization of $19.7 million.
- Return on equity was −146.1% and debt-to-equity 0.70.
Lifeward Ltd. (LFWD) Latest News
15 Sep
A peer-reviewed study finds Lifeward’s ReWalk exoskeleton yields significant gains in daily activity performance, user satisfaction, and pain reduction. Clinical validation of ReWalk exoskeleton supports increased market adoption and revenue growth for Lifeward.
31 Aug
Lifeward Ltd. appoints Josh Hexter interim chief executive officer and Rami Aviram chief financial officer. Executive appointments may affect strategic direction and market perception.
14 Aug
Lifeward Ltd. reported strong second quarter 2026 financial results driven by commercial execution and growth. Strong quarterly results signal major positive shifts in performance and investor outlook.
Lifeward Ltd. (LFWD) posted a Q2 loss and missed revenue estimates. Q2 loss combined with revenue miss points to weaker financial performance that can pressure near-term stock valuation.
5 Aug
Lifeward launches pilot program with Ottobock Care to expand national access to ReWalk Personal Exoskeleton. Pilot expands national distribution channels for core product via established partner.
7 Jul
Lifeward Ltd. secured up to $11.2 million through strategic financing to fund commercial expansion and growth initiatives. New capital directly enables commercial expansion that can materially lift revenue and market reach.
19 May
Lifeward appoints Dr. Keith D. Rose as Chief Medical Officer to expand its neurorehabilitation portfolio and advance the Biomed platform. New CMO hire strengthens medical leadership and supports ongoing portfolio growth without immediate major operational or financial shifts.
17 May
New price targets and valuation assumptions are shifting the outlook and narrative for Lifeward Ltd. (LFWD). New price targets and valuation changes can sway short-term investor sentiment and trading activity for Lifeward Ltd.
15 May
Lifeward Ltd. (LFWD) released its Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance and strategic outlook, poised to significantly sway investor sentiment and stock trajectory.
Lifeward Ltd. (LFWD) released Q1 2026 earnings call summary covering quarterly financial results, operational highlights, and future guidance. Q1 2026 earnings results, guidance, and strategic updates directly shape LFWD's financial trajectory and investor sentiment.
Lifeward Ltd. (LFWD) reported first quarter 2026 financial results. Quarterly financial results directly shape investor sentiment, stock valuation, and future performance expectations.
Lifeward Ltd addressed Q1 2026 earnings challenges while outlining growth initiatives in its earnings call. Q1 earnings call details on challenges and growth strategies point to moderate effects on near-term operations and sentiment.
Lifeward Ltd. (LFWD) reported a Q1 net loss and revenue below analyst estimates. Q1 loss and missed revenue estimates indicate weaker financial performance with moderate effects on investor sentiment and stock trajectory.
4 May
Lifeward presented new ReWalk data at ASIA 2026 Conference, demonstrating comprehensive longitudinal safety analysis for its powered exoskeleton. Comprehensive longitudinal safety data strengthens ReWalk exoskeleton's credibility for regulatory approval and market adoption.
25 Mar
Lifeward Ltd. (LFWD) successfully closed a strategic partnership with Oramed. Closing a strategic partnership qualifies as a major strategic move that could significantly boost Lifeward's competitive positioning and investor sentiment.
18 Mar
Lifeward Ltd (LFWD) Q4 2025 earnings call highlights strategic moves amid market challenges. Strategic moves in Q4 earnings could significantly boost LFWD's trajectory despite market headwinds.
Lifeward Ltd. (LFWD) released Q4 earnings snapshot, detailing financial results for the quarter. Q4 earnings snapshots deliver key financial metrics that often drive significant stock price movements and shape investor expectations for future performance.
Lifeward Ltd. (LFWD) reported fourth quarter and full year 2025 financial results, highlighting key revenue, profitability, and operational metrics. Quarterly and annual earnings reports signal financial health and future guidance, significantly impacting stock performance and investor confidence.
13 Mar
Lifeward Ltd. (LFWD) shareholders approved closing the strategic partnership with Oramed, forming a diversified biomedical company. Shareholder approval of the Oramed partnership enables diversification into biomedical operations, significantly altering Lifeward's strategic trajectory and market potential.
11 Mar
Lifeward Ltd. (LFWD) regained compliance with Nasdaq's minimum bid price requirement after implementing a strategy to meet the $1.00 threshold for 10 consecutive trading days. Regaining Nasdaq compliance eliminates delisting risk and enhances market visibility, significantly boosting investor sentiment and stock performance potential.
2 Mar
Lifeward Ltd. (LFWD) announced a collaboration with Shirley Ryan AbilityLab to expand access to the ReWalk Personal Exoskeleton, aiming to increase availability for users with spinal cord injuries and neurological conditions. Collaboration with a premier rehabilitation institute like Shirley Ryan AbilityLab broadens ReWalk exoskeleton access, driving potential revenue growth and strengthening market position.
26 Feb
ORMP enables shareholder participation in both ORMP and Lifeward Ltd. (LFWD) businesses, expected to enhance overall shareholder value. Enabling dual-business participation represents a major strategic move to boost LFWD shareholder value and market positioning.
25 Feb
Lifeward Ltd. (LFWD) to acquire a powered upper body exoskeleton featuring AI capabilities designed to restore upper body function for stroke survivors. Acquisition bolsters Lifeward's exoskeleton portfolio with AI-driven stroke rehab technology, enhancing competitive positioning and growth prospects.
17 Feb
Lifeward Ltd.'s ReWalk Personal Exoskeleton now receives coverage from Aetna, expanding to three of the largest Medicare Advantage insurers. Reimbursement coverage by Aetna and three major Medicare Advantage insurers significantly enhances product accessibility, adoption, and revenue potential for Lifeward.
13 Jan
Lifeward Ltd. has entered a strategic investment and partnership agreement with Oramed, aiming to create a diversified biomedical innovation company. This collaboration is expected to enhance Lifeward's capabilities in the biomedical sector, leveraging Oramed's expertise in oral drug delivery technology. The partnership is seen as a transformative move that could significantly impact both companies' growth trajectories and market positions. The partnership with Oramed represents a significant strategic move that could enhance Lifeward's market position and innovation capabilities.
Oramed Pharmaceuticals and Lifeward Ltd. have announced a strategic transaction aimed at enhancing their respective positions in the healthcare market. The collaboration is expected to leverage Oramed's innovative technologies alongside Lifeward's resources, potentially leading to new product developments and improved market reach. This partnership signifies a commitment to advancing therapeutic solutions and expanding their operational capabilities. The strategic transaction is likely to significantly impact Lifeward's future performance and market positioning.
19 Dec
Lifeward Ltd. has appointed Bob Marshall as the new Chairman of the Board. Marshall brings extensive experience in leadership and strategic development, which is expected to enhance the company's governance and direction. His appointment is part of Lifeward's efforts to strengthen its board and improve operational effectiveness. The appointment of a new chairman may influence the company's strategic direction and governance, but its overall impact on performance is expected to be limited.
17 Dec
Lifeward Ltd. has expanded the international distribution of its ReWalk® Personal Robotic Exoskeleton to Mexico, Thailand, and the United Arab Emirates. This move aims to enhance accessibility for individuals with mobility impairments in these regions, potentially increasing the company's market presence and customer base. Expanding distribution into new international markets is likely to significantly impact Lifeward's growth and investor sentiment.
3 Dec
Lifeward Ltd. has expanded reimbursement coverage for its ReWalk 7 personal robotic exoskeleton following the approval of prior authorization by Humana's Medicare Advantage Plan. This development is expected to enhance access to the exoskeleton for eligible patients, potentially increasing its market penetration and sales. The approval of reimbursement coverage by a major Medicare Advantage Plan is likely to significantly enhance market access and sales for Lifeward's ReWalk 7 exoskeleton.
17 Nov
UnitedHealthcare's Medicare Advantage Plan has approved prior authorization for the ReWalk 7 Personal Exoskeleton, a significant development for Lifeward Ltd. (LFWD). This approval allows patients to access the exoskeleton, which aids in mobility for individuals with spinal cord injuries. The decision is expected to enhance the market presence of Lifeward's innovative rehabilitation technology and improve patient outcomes. Prior authorization approval for the ReWalk 7 exoskeleton is likely to significantly enhance Lifeward's market position and financial performance.